Skip to main content

Table 2 The pooled ORs and 95%CIs for the association between TNF polymorphisms and prostate cancer susceptibility in total and stratified analysis

From: No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-α gene and susceptibility to prostate cancer: a comprehensive meta-analysis

VariablesNCase/ControlM-allele vs. W-allele
OR(95%CI) PhP
MW vs. WW
OR(95%CI) PhP
MM + MW vs. WW
OR(95%CI) PhP
rs1800629
 Total226936/76191.03 (0.92–1.16)0.001 0.5801.04 (0.93–1.17)0.040 0.4861.06 (0.94–1.18)0.013 0.353
 HWE187485/67921.03 (0,92–1.16)0.006 0.5841.04 (0,93–1.16)0.091 0.5091.05 (0,94–1.17)0.051 0.429
Ethnicity
 Asian8964/11371.03 (0.68–1.56)0.000 0.8811.04 (0.70–1.56)0.038 0.8451.09 (0.70–1.71)0.006 0.698
 Caucasian125626/58171.01 (0.94–1.08)0.223 0.8381.02 (0.94–1.11)0.525 0.6721.02 (0.94–1.11)0.433 0.625
 African-American2346/6650.93 (0.47–1.86)0.049 0.8430.87 (0.28–2.67)0.009 0.8040.90 (0.34–2.37)0.016 0.829
SOC
 HB142579/29731.02 (0.86–1.22)0.012 0.7871.00 (0.81–1.22)0.023 0.9721.01 (0.82–1.24)0.012 0.787
 PB84357/46461.04 (0.89–1.22)0.009 0.6001.04 (0.94–1.14)0.298 0.4831.04 (0.95–1.14)0.199 0.425
Genotyping
 Others5977/13091.07 (0.91–1.26)0.420 0.4200.97 (0.62–1.53)0.021 0.9001.07 (0.79–1.45)0.079 0.668
 Sequencing2546/5300.94 (0.75–1.19)0.166 0.6080.76 (0.34–1.70)0.055 0.5050.80 (0.41–1.55)0.086 0.506
 TaqMan74456/47331.04 (0.92–1.17)0.081 0.5201.02 (0.93–1.12)0.278 0.6381.02 (0.93–1.12)0.152 0.672
 PCR-RFLP5463/5620.74 (0.43–1.28)0.030 0.2800.90 (0.63–1.29)0.263 0.5650.89 (0.63–1.26)0.186 0.520
 ARMS-PCR3494/4851.56 (0.74–3.29)0.001 0.2391.28 (0.93–1.78)0.163 0.1351.54 (0.80–2.97)0.024 0.192
rs361525
 Total82212/22220.93 (0.66–1.32)0.007 0.6840.86 (0.52–1.41)0.000 0.5420.85 (0.52–1.39)0.000 0.525
 HWE62043/19791.11 (0,91–1.35)0.111 0.3211.02 (0,69–1.52)0.055 0.9051.05 (0,73–1.52)0.803 0.794
Ethnicity
 Asian3450/4700.72 (0.34–1.50)0.039 0.3800.55 (0.15–1.99)0.002 0.3600.54 (0.15–2.00)0.001 0.357
 Caucasian41698/16241.16 (0.94–1.44)0.673 0.1641.16 (0.94–1.44)0.673 0.1641.16 (0.94–1.44)0.673 0.164
 African-American164/126
Genotyping
 Others2178/1880.65 (0.47–0.89)0.111 0.0080.44 (0.09–2.25)0.002 0.3260.44 (0.08–2.28)0.002 0.325
 Sequencing2535/5111.07 (0.72–1.57)0.595 0.7460.90 (0.59–1.38)0.590 0.6330.98 (0.65–1.48)0.999 0.936
 PCR-RFLP2140/1502.59 (0.98–6.85)0.628 0.0552.68 (1.00–7.20)0.626 0.0502.68 (1.00–7.20)0.626 0.050
 TaqMan21359/13710.77 (0.30–2.01)0.017 0.5990.78 (0.28–2.20)0.011 0.6400.77 (0.28–2.13)0.013 0.620
rs1799724
 Total52914/31210.95 (0.84–1.07)0.169 0.3811.01 (0.80–1.27)0.054 0.9510.95 (0.83–1.07)0.120 0.390
 HWE32444/27350.99 (0,78–1.26)0.042 0.9300.98 (0,74–1.30)0.037 0.8960.99 (0,75–1.30)0.032 0.931
 Caucasian32253/24930.90 (0.79–1.03)0.403 0.1150.88 (0.76–1.02)0.196 0.0820.88 (0.76–1.02)0.400 0.089
  1. Ph: value of Q-test for heterogeneity test; P: Z-test for the statistical significance of the OR; HB hospital-based, PB population-based, SOC source of control, PCR-FLIP polymerase chain reaction and restrictive fragment length polymorphism, ARMS amplification refractory mutation system HWE, Hardy–Weinberg equilibrium of control group, W wild type-allele, M mutant-allele